Stockscreener 앱 받기
24.13
2.78%
-0.69
시간 외 거래:
24.13
전일 마감가:
$24.82
열려 있는:
$25
하루 거래량:
298.69K
Relative Volume:
0.94
시가총액:
$1.08B
수익:
$45.95M
순이익/손실:
$-48.88M
주가수익비율:
-21.68
EPS:
-1.1129
순현금흐름:
$109.67M
1주 성능:
-0.66%
1개월 성능:
-4.17%
6개월 성능:
+26.14%
1년 성능:
+237.01%
1일 변동 폭
$23.29
$25.25
1주일 범위
$22.78
$25.25
52주 변동 폭
$6.415
$32.63
Septerna Inc Stock (SEPN) Company Profile
명칭
Septerna Inc
전화
650-338-3533
주소
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
24.13 | 1.12B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | Raymond James | Strong Buy |
| 2025-12-15 | 개시 | Truist | Buy |
| 2025-11-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | 개시 | H.C. Wainwright | Buy |
| 2025-02-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-19 | 개시 | JP Morgan | Overweight |
| 2024-11-19 | 개시 | TD Cowen | Buy |
| 2024-11-19 | 개시 | Wells Fargo | Overweight |
모두보기
Septerna Inc 주식(SEPN)의 최신 뉴스
Septerna to Present at Bank of America Securities Health Care Conference - The Manila Times
Septerna, Inc. ($SEPN) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus - MarketBeat
Septerna, Inc. (NASDAQ:SEPN) Sees Significant Growth in Short Interest - MarketBeat
Stifel Initiates Septerna(SEPN.US) With Buy Rating, Announces Target Price $43 - Moomoo
Septerna (NASDAQ: SEPN) details 2026 vote on directors and auditor - Stock Titan
Septerna, Inc. (SEPN) reports Q4 loss, tops revenue estimates - MSN
Septerna (SEPN) price target increased by 34.39% to 46.41 - MSN
Are Options Traders Betting on a Big Move in Septerna Stock? - MSN
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Top Executives at Septerna, Inc. Make Bold Stock Purchases! - TipRanks
SEPN (Septerna Inc.) shares rise 7.46 percent after Q4 2025 loss lands narrower than consensus analyst estimates. - Xã Thanh Hà
Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial? - Sahm
Analysts Offer Insights on Technology Companies: Vicor (VICR), Ceragon Networks (CRNT) and Septerna, Inc. (SEPN) - The Globe and Mail
Truist Financial Maintains Septerna(SEPN.US) With Buy Rating - Moomoo
Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares - MarketBeat
Septerna Inc (SEPN) president and COO sells $97k in stock - Investing.com
[Form 4] Septerna, Inc. Insider Trading Activity - Stock Titan
Assessing Septerna (SEPN) Valuation After First Dosing In SEP-479 Phase 1 Trial - Sahm
SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target - TipRanks
Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy? - Sahm
HC Wainwright Reiterates Buy Rating for Septerna (NASDAQ:SEPN) - MarketBeat
H.C. Wainwright reiterates Septerna stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Septerna stock rating on trial start By Investing.com - Investing.com South Africa
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - Exchange Bitget
SEPTERNA INCPHASE 1 TRIAL DATA EXPECTED IN LATE 2026 OR EARLY 2027 - Moomoo
Septerna doses first patient in SEP-479 hypoparathyroidism trial By Investing.com - Investing.com Australia
Septerna doses first patients in SEP-479 trial - TipRanks
Insider Buy: Is Septerna Inc part of any ETF2026 Sector Review & Risk Controlled Stock Alerts - baoquankhu1.vn
Septerna (SEPN) Initiates Phase 1 Trial for Hypoparathyroidism T - GuruFocus
Movement Recap: Will Septerna Inc benefit from current market trendsWeekly Loss Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Septerna Begins Phase 1 Clinical Trial of SEP-479, an Oral PTH1R Agonist, for Hypoparathyroidism Treatment – Data Expected Late 2026/Early 2027 1 - Minichart
Septerna Begins Phase 1 Trial of Oral SEP-479 - TipRanks
Septerna doses first patient in SEP-479 hypoparathyroidism trial - Investing.com
Septerna begins Phase 1 trial of oral PTH1R agonist SEP-479; Phase 1 data expected late 2026–early 2027 - TradingView
Septerna (Nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism - Stock Titan
Septerna starts human testing of an oral drug for a lifelong disorder - Stock Titan
Septerna Inc (SEPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):